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SummAry
Quality and rate of preserved hearing are crucial to make hearing preservation surgery a viable treatment. A long-term experience with 
hearing preservation surgery, with tumour size and hearing as admission criteria, was evaluated to assess which size and hearing allowed a 
high rate of success. The hearing outcome in relation to size of tumour and pre-operative hearing was retrospectively reviewed in a consecu-
tive series of 115 cases of sporadic acoustic neuroma which were operated on with hearing preservation surgery. inclusion criteria were 
hearing with ≤ 30 dB pure tone average and ≥ 70% Speech Discrimination Score. The size was ≤ 15 mm in the first series of 51 cases, and 
≤ 10 mm in the second series of 64 cases. Pre-operative and post-operative pure tone average were measured at 0.5 to 4.0 Khz, and speech 
discrimination score at ≤ 40 dB above perception. Post-operative hearing within 30 dB pure tone average and 70% speech discrimination 
score was considered socially useful hearing and successful outcome. The change to 40 dB pure tone average and 60% speech discrimina-
tion score from a pre-operative 30 pure tone average/70% speech discrimination score was considered an acceptable outcome. Patients with 
a tumour of ≤ 10 mm size in the cerebello-pontine-angle and hearing within 20 dB pure tone average/80% speech discrimination score had a 
success rate of 76%. Patients with hearing between the 20 dB pure tone average/80% speech discrimination score and 30 dB pure tone aver-
age/70% speech discrimination score had a success rate of 41%, which increased to 53% if the limit to success was set at 40 dB pure tone 
average/60% speech discrimination score. Patients with a tumour larger than 10 mm or hearing worse than 30 dB pure tone average/70% 
speech discrimination score had a poor preservation rate. in conclusion, hearing preservation surgery on a ≤ 10 mm acoustic neuroma with 
good hearing had a high rate of success and appeared to be a realistic treatment option which could be integrated with observation and 
radiotherapy in updated guidelines of treatment.
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riASSunTo
La qualità ed il tasso di udito conservato sono cruciali nel rendere la chirurgia di conservazione dell’udito una terapia valida. La nostra 
esperienza con detta chirurgia ha preso come criterio di ammissione la dimensione del tumore ed il livello dell’udito e viene studiata con il 
proposito di accertare quale dimensione e quale udito hanno permesso un elevato tasso di successo. Si è compiuta una analisi retrospettiva 
del risultato uditivo in rapporto a dimensione tumorale e udito preoperatorio in una serie di 115 casi di neurinoma acustico sporadico, 
operati con chirurgia di conservazione dell’udito. I criteri di ammissione sono stati un udito preoperatorio di almeno 30 dB di Pure Tone 
Audiometry (PTA) e 70% di Speech Discrimination Score (SDS). La dimensione era non superiore a 15 mm in una prima serie di 51 casi, 
e non più di 10 mm in una seconda serie di 64 casi. L’udito è stato misurato con la media tonale pre- e postoperatoria alle frequenze da 
0,5 a 4 kHz e con il tasso di discriminazione vocale (SDS) a non più di 40 dB di amplificazione sopra la soglia di percezione. Un udito 
postoperatorio entro i 30 dB di PTA ed il 70% di SDS è stato considerato udito socialmente utile ed un successo. Un cambio a 40 dB PTA 
e 60% SDS è stato considerato un risultato accettabile se l’udito preoperatorio era 30 dB PTA e 70% SDS. I risultati sono stati i seguenti: 
i casi con tumore non superiore ai 10 mm in angolo ponto cerebellare e con udito entro i 20 dB PTA e 80% SDS hanno presentato un tasso 
del 76% di successo. I casi con udito preoperatorio compreso tra 20 dB PTA-80% SDS e 30 dB PTA-70% SDS hanno presentato un tasso 
di successo del 41%, che si eleva al 53% se il limite del successo è portato a 40 dB PTA e 60% SDS. I casi con tumore più grande di 10 mm 
e/o con udito peggiore di 30 dB PTA-70% SDS hanno avuto un tasso di conservazione nettamente inferiore. In conclusione, la chirurgia di 
conservazione dell’udito in tumori piccoli, ovvero non superiori a 10 mm e con udito buono può essere considerata una terapia valida che 
può essere integrata con l’osservazione e la radioterapia in aggiornate linee guida di trattamento.
pArole cHiAVe: Neurinoma dell’acustico • Schwannoma vestibolare • Chirurgia di conservazione dell’udito
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Introduction
hearing  preservation  was  the  last  goal  that  surgery  of 
acoustic neuroma added to the preservation of vital func-
tions and facial nerve. Since the historical papers by elliot 
and mc Kinney 1, house 2, rand and Kurze 3 and the ensu-
ing reports both with the middle cranial fossa approach 4-7 
and the sub-occipital approach 8-12 hearing preservation 
surgery continued to progress 13 14.
other treatment modalities, e.g. radiotherapy and observa-
tion, are challenging surgery and claim a high rate of pres-
ervation with minimally invasive treatment 15 or suggest 
observational treatment in small non-growing tumours 16.
The present report focuses on personal experience with 
hearing preservation surgery (hPS) to emphasize that this 
option should represent the first choice approach in small 
tumours with good hearing and should be integrated with 
observation, radiotherapy, and radical surgery in updated 
guidelines of treatment.
Material and methods
hPS was performed in 322 cases of sporadic vestibular 
schwannoma from 1976 to April 2009. The eligibility to 
surgery changed three times over the years (Table i) to 
become more and more restrictive with regard to tumour 
size and hearing level. The first series of 207 cases was the 
object of a previous article 17, the second series of 51 cases 
and the third series of 64 are reported herewith (Table ii). 
The trend to operate on smaller tumours with better hear-
ing could not always involve strict admission criteria, as 
follows.
The  eligibility  criteria  of  the  second  series  were:  size 
≤ 15 mm in the cerebello-pontine-angle (c.p.a.) and hear-
ing with ≤ 30 dB Pure Tone Audiometry (PTA) and ≥ 70% 
Speech Discrimination Score (SDS). The results led to the 
third series criteria of ≤ 10 mm in size, ≤ 30 dB PTA and 
≥ 70% SDS, and Auditory Brain response (ABr) with 
only moderate changes. As we could not take a rigid stand-
ing on criteria which were under trial, we operated also on 
patients exceeding the size and hearing limit: namely with 
good hearing in a larger tumour, or bad hearing on the 
non-tumour ear, or because of the patient’s choice. This 
approach was adopted in 32 out of 51 cases in the second 
series and in 35 out of 64 cases in the third series. Fac-
tors, in the second series, were PTA in 10 cases, size in 8 
cases, both PTA and size in 11 cases, PTA and SDS in 3. 
The exceeding factors of the third series were PTA in 17 
cases, size in 7 cases, both factors in 2 cases, ABr in 3, 
PTA + ABr in 2, size + ABr in 4 cases. The size of the tu-
mour was determined by the largest diameter in the c.p.a. 
at the enhanced T1 weighted magnetic resonance imaging 
(mri) 19. The extension of the tumour to the fundus of 
the internal auditory canal, both at mri and operation, 
was recorded, but it did not influence the choice of the 
approach. impaction on the fundus occurred in 57 cases, 
with a firm adherence in 27 of these patients. in 32 cases, 
the gap between the tumour and the fundus was 1-2 mm, 
in 26 it was ≥ 3 mm. The size of the tumour for each series 
is reported in Table ii.
hearing level was assessed with PTA and SDS. The PTA 
was carried out at 0.5, 1, 2 and 4 khz, the SDS at com-
fortable loudness or at 40 dB above perception whichever 
was less 18. These data were classified according to the 
AAohnS guidelines 18 and the Consensus meeting on 
Systems for reporting results 19 hereafter called the To-
kyo classification. The Tokyo grading is as follows:
•  class A is defined as an average pure tone hearing equal 
or better than 20 dB PTA and a speech discrimination 
score of at least 80%;
•  class B has the limit of 30 dB pTA/70% SDS;
•  classes c, D, e, F have a pTA of 20 dB steps and SDS 
of 10%, a better speech discrimination score than PTA 
makes the category of the outcome one class higher.
The tables on outcome show how the pre-operative cases 
of each class are distributed in the post-operative classes. 
outcome of every class was also reported as percent rate 
of the post-op class or classes over the pre-op class. A suc-
Table I. Study population and eligibility criteria to HPS and hearing out-
come according to AAOHNS classification.
HPS in 322 cases series I, II, III
Eligibility criteria
Hearing outcome
AAOHNS ’95, A-B classes
I 1976-2000, 207 cases
Ø ≤ 30 mm, hearing 50/50 27.5%
II 2000-2002, 51 cases
Ø ≤ 15 mm, hearing 30/70 32%*
III 2002-2008, 64 cases
Ø ≤ 10 mm, hearing 30/70 50%*
* Including cases OFF protocol.
Table II. Size of tumour in II and III series.
II series of 51 cases
IN eligibility criteria
19 cases
Average Ø 8.63 mm
Range 3-15 mm
OFF eligibility criteria
32 cases 
Average Ø 11 mm
Range 1-27 mm
III series of 64 cases
IN-eligibility criteria
29 cases
i.c. 18
Average Ø 7.3 mm
Range 4-9 mm
c.p.a. 11
Average Ø 6 mm
Range 4-8 mm
OFF-eligibility criteria
35 cases 
i.c. 11
Average Ø 6.8 mm
Range 4-10 mm
c.p.a. 24
Average Ø 11.2 mm
Range 1-26 mm
i.c.: intracanal tumor
c.p.a.: cerebello-pontine-angle tumorA. mazzoni et al.
78
cess was considered hearing within 30 PTA and 70 SDS 
which corresponds to Class A in the AAohnS and A and 
B in the Tokyo system. The failure was expressed with 
two figures depending on considering, or not, a failure, 
the drop to the next lower class.
The surgical technique was the retro-sigmoid (rS) ap-
proach with retro-labyrinthine meatotomy as already de-
scribed 17, in 96 cases, and the middle cranial fossa (mCF) 
approach in 19 cases of intra-meatal tumours.
with the retro-sigmoid approach, the patient was placed 
in a lateral (park bench) position with the head contra-lat-
erally turned of 30°. The surgical table was further rotated 
20-30° during exposure of the lateral end of the acoustic 
meatus.
intra-operative monitoring was performed on the Vii c.n. 
with electromyography (emg), and the auditory system 
with ABr and compound action potential (CAP) of the 
cochlear  nerve.  Facial  nerve  function  was  assessed  18 
months post-operatively and classified according to house 
Brackmann grading. The follow-up involved an enhanced 
mri at 1, 3, 6, 10 years to assess a persistent tumour. 
hearing was investigated with PTA and speech audiom-
etry at 1 and 6 months and yearly thereafter. Pre-operative 
ABr had an important role for admission to hPS in the 
third series of cases. Absence of ABr was an absolute 
contraindication to hearing preservation. Absence of wave 
iii, latency of wave V superior to 7 ms and i to V interpeak 
latency superior to 5.5 ms were considered unfavourable 
factors and relative contra-indications. They were evalu-
ated together with the size of the tumour, PTA and SDS to 
decide admission to hPS, mostly in borderline cases.
Results
An overall view of the complete surgical material of 322 
cases is reported in Table i. The first series 17 involved the 
elegibility limit of 30 mm size, 50 dB PTA and 50% SDS. 
The complications of the second and third series are re-
ported in Table iii. The facial nerve outcome of the 115 
cases is reported in Table iV. overall, 94% of the cases 
had a house Brackmann (hB) degree 1 or 2, 6% hB 3. 
The 7 cases with hB 3 paresis were 2 intra-meatal tu-
mours operated on with the mCF approach, 5 cases with 
the rS approach and size 4, 22, 22, 26, 17 mm, respec-
tively. in the group of 19 intra-canalicular tumours, oper-
ated upon with the mCF approach, there were 4 cases of 
hB 2 and one case of hB 3. in the group of 54 cases of 
rS approach, in ≤ 10 mm tumours the hB outcome was 1 
in all cases except for two cases of hB 2 and one of hB 3. 
in one of the 22 mm tumours, the anatomical continuity 
was lost and re-established at the lateral end of the meatus 
with a recovery to hB 3 function.
The hearing outcome of the second and the third series is 
recorded for the group within the eligibility criteria and 
the group beyond eligibility, according to the AAohnS 
and Tokyo systems. in the eligible group of the second 
series (Table V), the success rate was AAoHNS class A 
37%, Class A+B 74%. According to the Tokyo system, 
the rates were 30% Class A and 60% Class A+B. The 
failure rate ranged from 26% to 53%, according to the 
pre-operative class and which post-operative class was 
considered a success.
The third series had AAohnS rates of 48% post-opera-
tive Class A and a 76% Class A+B. The failures as Classes 
C and D were 24% but increased to 51% if Class B was 
considered a failure. The rates according to the Tokyo 
classification were post-operative 42% Class A and 74% 
Class A+B for the pre-operative Class A cases. in the pre-
operative Class B, the outcome was 40% Class B and 70% 
Class B+C. The failures were 39% or 27.5% if C Class of 
pre-operative B was or was not considered a failure.
The cases which were beyond the admission limit because 
of size and/or hearing amounted to a total of 67 for the 
two series and had a failure rate ranging from 89% to 76% 
both in the AAohnS 18 and Tokyo system 19, respectively, 
and success of 37% to 50% in A cases and 23% to 16% in 
B cases (Table Vii).
A total of 42 cases of the entire case material entered 
the limits of 10 mm size, 30 dB PTA and 70% SDS and 
are grouped together in Table Viii. This group is rep-
resentative of the current criteria of elegibility to hPS 
and forms the end-point of our experience. with the 
AAohnS system 18, Class A occurred in 48%, Classes 
A+B in 83%. more details are seen with the Tokyo sys-
tem 19. Class A occurred in 26% and Classes A and B 
in 62%. The outcome may be more appropriately re-
Table III. Complications in 115 cases (II-III series).
Patients Complications Outcome
F, 58 y, RS a. Cerebellar infarction →  revision 
surgery → haemiparesis
Regression 
to normal
M, 49 y, RS a. CSF leak 7 months 
postop → revision surgery
Normal
F, 47 y, RS a.  CSF leak, post-op → revision 
surgery 
Normal
M, 32 y, MCF a. CSF leak, post-op → revision 
surgery
Normal
y: years; a: approach; RS: retro-sigmoid; MCF: middle cranial fossa
Table IV. Facial nerve function, post-operative outcome, 115 cases (II-
III series), according with House Brackmann grading.
Post-op. VII HB° No. patients %
I 98 85.2%
II 10
(1 case II° HB pre-op)
8.6%
(I-II° HB: 93.9%)
III 7 6.2%
Total 115hearing preservation surgery in acoustic neuroma
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ferred to the pre-operative Class A and Class B and de-
tails whether the post-operative hearing kept the class 
or dropped by 10dB/10% score to the next lower class. 
The Class A cases kept their Class in 44%, and dropped 
to the B Class in 32% cases, thus totalling 76% within 
the B Class or 64% within the 30 dB PTA and 70% SDS 
level. This discrepancy between rate of the class and 
rate of the PTA/SDS level is due to the class upgrading 
in cases with class of SDS better than class of PTA, as 
set by the Tokyo classification 19. There were 7 cases up-
graded to B from C Class. That is four pre-operative A 
and three pre-operative B. There were 6 cases upgraded 
from D to C, three belonging to pre-operative A, three 
to pre-operative B. overall, the rate of upgrading was 
31% in the selected series of 42 cases, it was 19% in the 
complete series of 115 cases.
Table V. Hearing outcome in 19 eligible cases (≤ 15 mm, ≤ 30 dB PTA/70% SDS) of II series.
AAOHNS No. cases Post-op. A Post-op. B Post-op. C  Post-op. D
Pre-op. A 19 7 7 / 5
TOKYO No. cases Post-op. A Post-op. B Post-op. C Post-op. D Post-op. E Post-op. F
Pre-op. A 10 3 3 1 / / 3
Pre-op. B 9 / 3 3 1 / 2
Total 19 3 6 4 1 / 5
Table VI. Hearing outcome in 29 eligible cases (≤ 10 mm, ≤ 30 dB PTA/70% SDS) of III series.
AAOHNS No. cases Post-op. A Post-op. B Post-op. C  Post-op. D
Pre-op. A 29 14 8 1 6
TOKYO No. cases Post-op. A Post-op. B Post-op. C Post-op. D Post-op. E Post-op. F
Pre-op. A 19 8 6 2 / / 3
Pre-op. B 10 / 4 3 / / 3
Total 29 7 9 5 / / 6
Table VII. Hearing outcome in 67 non-eligible cases of series II and III.
AAOHNS No. cases Post-op. A Post-op. B Post-op. C  Post-op. D
Pre-op.  A 19 7 / 2 10
B 39 1 8 5 25
C 9 / / 1 8
Total 67 8 8 8 43
TOKYO No. cases Post-op. A Post-op. B Post-op. C  Post-op. D Post-op. E Post-op. F
Pre-op.  A 14 / 7 / / / 7
    B 30 1 3 3 1 / 22
    C 19 / / 3 5 1 10
    D 4 / / / 1 / 3
Total 67 1 10 6 7 1 42
Table VIII. Hearing outcome in 42 (≤ 10 mm, ≤ 30 dB PTA/70% SDS) cases of II and III series.
AAOHNS No. cases Post-op.. A Post-op. B Post-op. C  Post-op. D
Pre-op. A 42 20 15 1 6
TOKYO No. cases Post-op. A Post-op. B Post-op. C Post-op. D Post-op. E Post-op. F
Pre-op. A 25 11 8 (3) 2 (2) 1 / 3
Pre-op. B 17 / 7 (4) 6 (4) 1 / 3
Total 42 11 15 (7) 8 (6) 2 / 6
(…): cases with upgraded class.A. mazzoni et al.
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if the class upgrading is not applied, as set by the Sanna 
classification 19, the success is less; 64% of the Class A 
remain within Class A or B and 53% of Class B within 
Class B or C.
The Class B cases had 41% within the class and a total of 
76% within the C Class and 53% in the 40 dB PTA and 
60% SDS limit. overall, 76% of the 42 cases fell within 
the next lower class. The failures with the AAohnS were 
52.5% as classes B, C, D or 17.5% as Classes C, D. with 
the Tokyo class the failures were 33% or 19% if C Class 
was not considered a failure in pre-operative B cases. it is 
noteworthy to record the post-operative change of PTA. 
The 25 pre-operative Class A cases were 19 post-opera-
tive Class A-B cases; there was no loss in 6 cases, and an 
average loss of 14.6, range 5 to 30 dB, in 13 cases. The 
17 pre-operative Class B cases were 13 post-operative B 
or C Class cases, with no loss in 2 cases and an average 
loss of 15 dB, range 3 to 31 dB, in the remaining 11 cases. 
recording of the post-operative PTA adds information to 
the class grading.
Discussion
Hearing outcome
unilateral profound hearing loss or deafness are a com-
mon evolution both in untreated or treated acoustic neu-
roma and involve such disabilities as the understanding 
of speech in noise, localizing a sound source 20-22 and an 
unpleasant feeling in a noisy context. rehabilitation of 
the deaf ear with the contra-lateral routing of signal or 
with the bone anchored hearing aid 23 eliminate the head 
shadow effect but do not restore the binaural hearing 24. 
hearing preservation of the tumour ear is the natural goal 
of every treatment. hPS over the years faced a series of 
unfavourable  conditions. They  were:  the  limited  diffu-
sion of this treatment, the rarity of cases, the difficulty of 
obtaining good results and the widespread acceptance of 
non-surgical treatments.
our 30 years’ involvement with hPS passed through dif-
ferent stages with different indications and outcomes (Ta-
ble i). outcomes of the first series of 207 cases 17 showed 
that only the few small tumours with good hearing allowed 
a reasonable rate of success. For example, 45 out of 68 
cases of preserved hearing, in the group of 150 cases, had 
a ≤ 10 mm size, 13 had a 10-15 mm size and 10 were over 
15 mm. The admission criteria were then changed in the 
second and third series with the aim of improving rate and 
quality of preserved hearing. There followed an improve-
ment in hearing preservation (Tables V-Vi) which took 
place with the more restrictive admission criteria up to 
the conclusive limit of 30 dB PTA, 70% SDS and 10 mm 
size. Tumours beyond this limit showed a substantial drop 
in outcome quality (Table Vii).
Although a satisfactory hearing level cannot be judged 
only on the basis of audiometric criteria for the worse hear-
ing ear 18, the hearing outcome is currently being consid-
ered a success if the level is equal to, or better than, 30 dB 
PTA and 70% SDS 25, which corresponds to the AAohnS 
class A and to the Tokyo classes A and B. Tables V and 
Vi report the number of classes A and A+B for the two 
systems. The Tokyo Class B includes the cases with a PTA 
Class C and SDS Class B or A, which are promoted to 
the next higher class than pTA. The last series (Table Vi) 
with a success rate of 48% to 76% of the AAohnS 18 and 
42% to 74% of Tokyo 19 reflects the improvement with 
respect to the previous series. The conclusive point of our 
experience is outlined in Table Viii which groups together 
the 42 cases of 10 mm size belonging to the second and 
third series. The Tokyo Classification yields a success rate 
as shown in Tabella Viii. Tumours with a pre-operative 
hearing equal to or better than the 20 dB pTA and 80% 
SDS remain in the B Class at a rate of 76% and within the 
30/70 level in 64%. The cases with pre-operative hear-
ing ranging between the 20/80 and 30/70 level keep their 
Class B in 41% and drop into class C in 35%, totalling 
66% within the next lower class and 53% within the limit 
of 40 PTA and 60 SDS. The slight loss produced by sur-
gery then allowed success with the 20 dB PTA/ 80% SDS 
cases, whereas it pushed the 30 dB PTA/70% SDS cases 
to the 40 dB PTA/ 60% SDS level. whether this Class 
C may be a true failure, with no benefit to the patient, 
is not clear and also depends upon the contra-lateral ear, 
the binaural hearing in silence and noise and the effect of 
hearing rehabilitation. we conclude that hPS has a high 
rate of success and can be considered a realistic form of 
treatment in tumours size ≤ 10 mm in the c.p.a. and hear-
ing equal to, or better than, 20 dB pTA and 80% SDS. 
if the hearing limit is placed at 30 dB PTA/70 SDS, the 
indication to hPS is still advisable.
The class upgrading, when SDS belongs to a better class 
than PTA, as set by the Tokyo classification, disrupts the 
equivalence B class 30 dB pTA/70 SDS, or c class 40 dB 
PTA/60 SDS. Adopting the AAohnS 18 or the modified 
Sanna 19 classifications, which do not use the class upgrade, 
results in the PTA alone dictating the class. This occurs as, 
with diverging PTA and SDS, the worst is selected, and 
PTA is constantly worse, at least in our material.
Table  IX.  Guidelines  of  treatment  in Acoustic  Neuroma  (Non-cystic 
acoustic neuroma, size as largest diameter in c.p.a.).
Size Hearing Treatment
≤ 10 mm Good hearing
Bad hearing
→ HPS
→ * Observation
10 to 15 mm (Good/ Bad hearing)
MRI 1 year
Growth → S or RT
No growth → Observation
15 to 25 mm → Surgery or RT 
> 25 mm → Surgery
* Observation involves MRI follow-up after 1, 2, 3, 4, 5, 7, 9,14, 20 years. Age, co-
morbidity, surgical risk can address to non-surgical treatment.hearing preservation surgery in acoustic neuroma
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The small size and good hearing were commonly consid-
ered favourable prognostic factors to hPS 26. The good re-
sults in this group of patients, however, were not obvious in 
the large series including cases with a lesser pre-operative 
hearing. Disregard of this aspect was present in critical re-
views on hPS 25 and in a cautious attitude on the role of 
hPS 16. These judgements contributed to the acceptance of 
the non-surgical treatments which therefore prevented the 
patients from being offered a hearing preservation option.
The dilation of the internal auditory canal caused by the 
tumour was demonstrated to be of prognostic value. when 
the diameter of the canal, as seen at bone window CT 
was much larger than the normal side, the cochlear nerve 
was thinned out by the tumour and more likely to loose 
function at dissection. The monitoring of the CAP (com-
pound action potential) allowed a brief interval of time 
between the surgical action and its effect on the cochlear 
nerve function. The noxious manoeuvre could be, to some 
degree, corrected. The nerve function usually changed or 
was lost at dissecting between the posterior pole of the 
tumour and the meatus. it seemed that a direct, or even 
an indirect, distension of the cochlear nerve was the most 
common factor to damage it or make it vulnerable to a 
further, even slight, handling.
in the literature, extension of the tumour to the fundus 
of the auditory canal was felt to contraindicate the retro-
sigmoid approach, as it implied a blind dissection with 
risk of damaging the nerves or leaving a residual tumour. 
The retro-labyrinthine meatotomy, as well as the endos-
copy-assisted approach 27 can solve this problem. we had 
no residual tumour 28 or nerve losses, at dissection, on the 
distal half of the canal.
understanding the differences between classifications is 
important for their convenient use. The PTA at 0.5 to 3 
Khz is likely to be better than a PTA at 0.5 to 4 Khz and 
to put a borderline case in a better class. Testing the SDS 
with a limited amplification, for example at 40 dB above 
the threshold 18 involves often a lower figure than would 
be without a limit. we adopted this more realistic method 
also with the Tokyo classification 19. The word recogni-
tion Score 29 gave a 10% higher figure of success than the 
other systems in our material. The Tokyo A and B classes 
outlined better the top quality outcome and demonstrated 
better the correlation between a good pre-operative hear-
ing and success. Stratifying the hearing levels in classes 
may involve an unnoticed effect. hearing may change to 
a lower level and still keep the original class, or it may be 
subject to a small change and drop to the lower class. This 
fact is likely to take place with the hearing levels situated 
at the two extremes of each class.
Treatment options
experience shows that hPS is mainly directed to the small 
tumour for which other options such as observation and ra-
diotherapy are available. A rational choice of treatment can 
be pursued on the basis of the natural course of the disease 
and the outcome of the active treatment. This observation is 
supported by a strong argument, the spontaneous and stable 
arrest of growth in 71.1% of tumours lying in the c.p.a. and 
in 83% intra-meatal tumours 16. Stereotactic radiotherapy 
claims a no-growth rate of as much as 94-98% 15 30 31. Two 
points deserve attention. one is how these treatments af-
fect hearing, the other which is the outcome of the cases 
submitted to secondary surgery because of growth. obser-
vation involves a loss of hearing even in non-growing tu-
mours 32-34. Successful radiotherapy leads to no change in 
hearing in the short term 15 30 but progressive and severe loss 
in the mid-long term is a common experience only recently 
reported 35-37. The second point concerns the principle that 
the outcome of observation and radiotherapy should in-
clude also the results of secondary surgery on the grow-
ing tumour. The observation in an extra-meatal tumour in-
volves surgery when the tumour shows a detectable growth 
> 15 mm, which takes place in 29% of cases 16. This means 
surgery in tumours over 18 mm, in which the predictable 
outcome is deafness, and a Vii cranial nerve loss of 3 HB 
degrees or worse in approximately 17% of cases 38.
The intra-meatal tumour has a 17% chance of growing 
extra-meatal 16 while the tumour remaining intra-meatal 
shows a spontaneous loss of class A-B hearing in ap-
proximately 50% or more of cases 33 34. while surgery and 
observation have the support of reliable studies, radiation 
requires the support of methodologically correct studies. 
The current reports take the lack of growth as an index 
of success and point to indicate a 94-98% rate of suc-
cess 15 30 31. This is, however, an equivocal figure, as the 
vast majority of small tumours spontaneously stop grow-
ing. rT should, therefore, be used in the case of grow-
ing tumours. observing a tumour in order to treat it when 
growth is proven, is in itself a further cause of hearing 
change adding up to the late effect of radiation. which is 
the efficacy of rT on a small growing tumour? no reports 
on this subject are available yet. we can arbitrarily com-
bine data from various sources and reach a provisional 
answer. if the failure rate of 2-6% is referred to the 29% 
of growing tumours, as the natural history states 16, the 
corrected failure rate should be in the range of 7-22%. The 
necessary operation would result in deafness, and a facial 
loss of at least 3 hB degrees in a high rate of cases 39 40. in 
conclusion, the overall outcome of the complete course of 
treatment with observation or radiation in small tumours 
with good hearing includes a succession of losses, e.g., 
the initial hearing loss, the hearing loss of the observation, 
and the further deafness and facial loss of the secondary 
surgery. The amount of these sequelae is not inferior to 
those produced by hPS in the complete group of similar 
cases and may reverse the view that observation or radia-
tion are more conservative. hPS involves, however, other 
and less favourable aspects to be discussed. These are the 
morbidity of the surgery and the long-term decay of the A. mazzoni et al.
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preserved hearing. our patients returned to their pre-op-
erative life and work within one to three months, with the 
exception of 5 cases which took longer. The post-operative 
pain in the back of the neck, radiating to the head, faded 
away after the first year. These problems, with their loss 
of quality of life, should be weighed against the lifetime 
psychological burden of harbouring a “benign tumour”. 
The preserved hearing is subject to long-term decay with 
a different rate and degree 35. in a ten-year follow-up of 
our first series, this was proportional to the initial post-op-
erative loss. The hearing of the AAohnS Classes A and B 
dropped by one class with a 16% rate of cases
Updating the guidelines of treatment
The increasing number of small tumours and the new infor-
mation on the natural history and the outcome of surgery 
and radiotherapy offer the opportunity to update the guide-
lines of treatment. This involves a balance between such 
different factors as size and growth of the tumour, hearing 
and facial nerve function, age and co-morbidity, desire of 
the patient, as well as the burden imposed on his/her physi-
cal and emotional condition. The minimal morbidity is the 
common goal both of active treatments and observation. 
Tschudi et al. 41 suggested watchful expectation and surgery 
or radiotherapy in the event of proven growth. Stangerup 
et  al.  16  proposed  observation  for  tumours  smaller  than 
15 mm and active treatment for tumours growing > 2 mm 
above this size. The 15 mm limit was to avoid the increased 
surgical morbidity on the Vii nerve with a larger tumour. 
This criterion, however, entails operating on ≥ 18 mm tu-
mours with a risk of facial nerve loss which is reported to 
be as high as 17% of hB grade iii or worse in the 15 to 
25 mm tumour 39. Surgery on smaller tumours lowers the 
facial risk to 9% 38, but it requires the non-growing tumour 
be excluded from unnecessary treatment. To this aim, an 
mri control within the next 12 months, showing absence 
of growth, can be a predictor of no growth 41-43 with a 5.6% 
chance of missing a later arrest of growth 44.
our guidelines (Table iX) include hPS, conventional sur-
gery, observation and radiotherapy, and select the treatment 
on the basis of size and growth of the tumour, hearing and the 
patient-related factors such as age, co-morbidity, surgical risk 
and the individual’s preference. if a patient with a ≤ 10 mm 
tumour presents good hearing within 30 dB PTA/70% SDS 
and ABr with only moderate changes, hPS is offered as first 
choice treatment. The only one exception could be a tumour 
with 100% SDS, in which the chance of good long-term 
hearing 34 suggests observational treatment. if hearing is bad, 
observation with mri follow-up is the best option, as it al-
lows treatment of the non-growing tumour to be avoided. A 
tumour between 10 and 15 mm in size is submitted to active 
treatment when annual mri shows evidence of growth. A 
> 15 mm tumour involves surgery or radiotherapy. The sur-
gical option changes to observation or radiotherapy depend-
ing on patient-related factors. Age, and/or co-morbidity with 
increased surgical risks indicate the need for observation or 
radiotherapy. The patient’s desire to choose between differ-
ent options is decisive. The case of the > 10 mm tumour with 
good hearing and a lesser chance of hearing preservation is a 
matter for patient’s and doctor’s judgement.
updating the treatment of acoustic neuroma involved the 
evaluation of the complete course of each option includ-
ing the management failures, and indicated the treatment 
with the least morbidity. Timely treatment is more effec-
tive with early diagnosis especially when active treatment 
is debated. The suggested guidelines, indicate that radi-
otherapy needs better data regarding its efficacy on the 
growing tumour. early surgery on a small tumour, on the 
other hand, can benefit more from complete data on the 
rate and pattern of tumour growth.
Conclusions
unilateral hearing loss, or deafness, are common events 
in acoustic neuroma and cause serious handicaps to in-
ner, social and professional life. The hPS addressed to 
this problem was of limited success and raised doubts of 
being an unrealistic goal due to the few eligible cases and 
insufficient rate of success. more recent progress, how-
ever, appears to favour the important role of hPS. These 
include early diagnosis of small tumours, the selection of 
cases with a favourable surgical prognosis, the advances 
made in surgery thanks to the experience of the surgeon 
and use of monitoring. This report on our experience with 
hPS aims to contribute to the present debate and focuses 
on two points. Does hPS offer a benefit which makes the 
operation worthwhile? Are there alternative treatments?
1. in our experience, hPS offers a success rate of 76% 
in small tumours with good hearing. The limit of eleg-
ibility to hPS is size ≤ 10 mm in the c.p.a. and hearing 
equal to or better than 20 dB pTA and 80% SDS, and 
ABr with only moderate changes. Cases below this 
limit, but still within the 30 PTA and 70% SDS, have a 
66% chance of maintaining the same class or the class 
immediately below.
2. Alternative treatments should be judged on the basis 
of the outcome of the entire course of the treatment. 
observation  and  STrT  are  the  options  allowing  a 
non-surgical approach, with the functional preserva-
tion and maintenance of the tumour. with both these 
options, however, the better preservation, which has 
been claimed, is not obtained. hearing is inevitably 
impaired and the facial nerve is subject to a higher risk 
if the complete course of treatment, with the obligatory 
surgery on a growing tumour is accounted for.
hPS presents its own drawbacks, e.g. the fate of hearing 
cannot be predicted in the individual case, the operation is 
itself a disease. These inconveniences represent the price 
for recovery and belong to the balance of “pro and contra” 
to be discussed with the patient.hearing preservation surgery in acoustic neuroma
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